SARCOPENIC OBESITY IN THE ERA OF INCRETIN-BASED THERAPIES: DIAGNOSTIC CHALLENGES, THE RISK OF MUSCLE MASS LOSS, AND PREVENTION STRATEGIES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5940Keywords:
Sarcopenic Obesity; Sarcopenia; Obesity; Semaglutide; Tirzepatide; Incretin-Based TherapyAbstract
Introduction and purpose. Sarcopenic obesity (SO) is defined by the coexistence of excess adiposity and reduced muscle mass and function and is associated with disability, frailty, cardiometabolic disease, and increased mortality. This review aims to summarize current evidence on the definition and diagnosis of SO, assess the effects of incretin-based therapies on body composition, with a focus on practical strategies to reduce the risk of clinically relevant muscle loss during obesity treatment.
Material and methods. This manuscript was prepared as a structured narrative review based on publications identified in PubMed/MEDLINE, Google Scholar, and the Cochrane Library.
Results. Current evidence suggests that semaglutide and tirzepatide produce significant and sustained reductions in body weight and fat mass, including visceral adipose tissue, while also being associated with a decrease in absolute lean body mass. These changes should not be interpreted automatically as clinically relevant skeletal muscle loss. However, older adults, frail individuals, and patients with low muscle reserve are more susceptible, especially without adequate protein intake, resistance exercise, and regular monitoring.
Conclusions. Incretin-based therapies represent a major advance in obesity treatment; however, in patients at risk of SO, they should be used within a multimodal strategy aimed at preserving muscle mass and function.
References
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., et al. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://doi.org/10.1093/ageing/afy169
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., et al. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obesity Facts, 15(3), 321–335. https://doi.org/10.1159/000521241
Gao, Q., Mei, F., Shang, Y., Hu, K., Chen, F., Zhao, L., et al. (2021). Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis. Clinical Nutrition, 40(7), 4633–4641. https://doi.org/10.1016/j.clnu.2021.06.009
Batsis, J. A., & Villareal, D. T. (2018). Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology, 14(9), 513–537. https://doi.org/10.1038/s41574-018-0062-9
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024). Sarcopenic obesity in older adults: A clinical overview. Nature Reviews Endocrinology, 20(5), 261–277. https://doi.org/10.1038/s41574-023-00943-z
Purcell, S. A., Mackenzie, M., Barbosa-Silva, T. G., Dionne, I. J., Ghosh, S., Olobatuyi, O., et al. (2021). Prevalence of sarcopenic obesity using different definitions and the relationship with strength and physical performance in the Canadian Longitudinal Study on Aging. Journal of Cachexia, Sarcopenia and Muscle, 12(1), 145–155. https://doi.org/10.3389/fphys.2020.583825
Gortan Cappellari, G., Zanetti, M., Donini, L. M., & Barazzoni, R. (2024). Detecting sarcopenia in obesity: Emerging new approaches. Current Opinion in Clinical Nutrition and Metabolic Care, 27(5), 402–409. https://doi.org/10.1097/MCO.0000000000001062
Liu, C., Wong, P. Y., Chung, Y. L., Chow, S. K. H., Cheung, W. H., Law, S. W., et al. (2023). Deciphering the “obesity paradox” in the elderly: A systematic review and meta-analysis of sarcopenic obesity. Obesity Reviews, 24(2), e13534. https://doi.org/10.1111/obr.13534
Morikawa, M., Lee, S., Makino, K., Harada, K., Katayama, O., Tomida, K., et al. (2023). Sarcopenic obesity and risk of disability in community-dwelling Japanese older adults: A 5-year longitudinal study. Journal of the American Medical Directors Association, 24(8), 1179–1184.e1. https://doi.org/10.1016/j.jamda.2023.03.008
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Suppl. 1), A16–A17. https://doi.org/10.1210/jendso/bvab048.030
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024). A systematic review of the effect of semaglutide on lean mass: Insights from clinical trials. Expert Opinion on Pharmacotherapy, 25(5), 611–619. https://doi.org/10.1080/14656566.2024.2343092
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl. 4), 16–27. https://doi.org/10.1111/dom.15728
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024). Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss? Circulation, 150(16), 1288–1298. https://doi.org/10.1161/CIRCULATIONAHA.124.067676
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., et al. (2024). The effect of tirzepatide on body composition in people with overweight and obesity: A systematic review of randomized, controlled studies. Diseases, 12(9), 204. https://doi.org/10.3390/diseases12090204
McCrimmon, R. J., Catarig, A. M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., et al. (2020). Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia, 63(3), 473–485. https://doi.org/10.1007/s00125-019-05065-8
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., et al. (2022). Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: A 26-week prospective real-life study. Nutrients, 14(12), 2414. https://doi.org/10.3390/nu14122414
Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., et al. (2018). International clinical practice guidelines for sarcopenia (ICFSR): Screening, diagnosis and management. The Journal of Nutrition, Health & Aging, 22(10), 1148–1161. https://doi.org/10.1007/s12603-018-1139-9
Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association, 14(8), 542–559. https://doi.org/10.1016/j.jamda.2013.05.021
Villareal, D. T., Aguirre, L., Gurney, A. B., Waters, D. L., Sinacore, D. R., Colombo, E., Armamento-Villareal, R., & Qualls, C. (2017). Aerobic or resistance exercise, or both, in dieting obese older adults. The New England Journal of Medicine, 376(20), 1943–1955. https://doi.org/10.1056/NEJMoa1616338
Frimel, T. N., Sinacore, D. R., & Villareal, D. T. (2008). Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Medicine & Science in Sports & Exercise, 40(7), 1213–1219. https://doi.org/10.1249/MSS.0b013e31816a85ce
Sardeli, A. V., Komatsu, T. R., Mori, M. A., Gáspari, A. F., & Chacon-Mikahil, M. P. T. (2018). Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: A systematic review and meta-analysis. Nutrients, 10(4), 423. https://doi.org/10.3390/nu10040423
Verreijen, A. M., Engberink, M. F., Memelink, R. G., van der Plas, S. E., Visser, M., & Weijs, P. J. M. (2017). Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: A randomized controlled trial. Nutrition Journal, 16(1), 10. https://doi.org/10.1186/s12937-017-0229-6
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., et al. (2024). Nutritional considerations with antiobesity medications. Obesity, 32(9), 1613–1631. https://doi.org/10.1002/oby.24067
Assyov, Y., Nedeva, I., Spassov, B., Gerganova, A., Velikov, T., Kamenov, Z., et al. (2024). Nutritional management and physical activity in the treatment of sarcopenic obesity: A review of the literature. Nutrients, 16(15), 2560. https://doi.org/10.3390/nu16152560
Di Vincenzo, O., Minnetti, M., Baker, J. L., Barazzoni, R., Boyland, E., Busetto, L., et al. (2025). European Association for the Study of Obesity position statement on the diagnosis and management of obesity in older adults. Obesity Facts, 1–20. Advance online publication. https://doi.org/10.1159/000549751
Coelho-Junior, H. J., Calvani, R., Azzolino, D., Picca, A., Tosato, M., Landi, F., et al. (2022). Protein intake and sarcopenia in older adults: A systematic review and meta-analysis. International Journal of Environmental Research and Public Health, 19(14), 8718. https://doi.org/10.3390/ijerph19148718
Chen, A. S., & Batsis, J. A. (2025). Treating sarcopenic obesity in the era of incretin therapies: Perspectives and challenges. Diabetes, 74(12), 2179–2190. https://doi.org/10.2337/dbi25-0004
Lin, X., & Li, H. (2021). Obesity: Epidemiology, pathophysiology, and therapeutics. Frontiers in Endocrinology, 12, 706978. https://doi.org/10.3389/fendo.2021.706978
Walston, J. D. (2012). Sarcopenia in older adults. Current Opinion in Rheumatology, 24(6), 623–627. https://doi.org/10.1097/BOR.0b013e328358d59b
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., et al. (2020). World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine, 54(24), 1451–1462. https://doi.org/10.1136/bjsports-2020-102955
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Anna Wolszczak, Weronika Martynowska, Michał Hajt, Dastin Misiaszek, Alicja Graczyk, Piotr Ciecierski, Natalia Grabowska, Jakub Motor, Paulina Patrycja Turzyńska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
